The Spanish health AI sector will go from moving €130 million in 2022 to generating €2.5 billion in 2030. Companies such as Almirall, Grifols or Faes...
There are also signs to anticipate the entry into a consolidation phase of the digital health business. The merger and acquisition (M&A) of companies in this...
In December 2023, the company reached an agreement to acquire the entire share capital of the Chinese start-up Gracell Biotechnologies for a price that could reach...
The path laid out by general pharmaceutical legislation, according to the Asebio study's conclusions, makes it less likely to achieve objectives related to, for example, rare...
With the transaction, Sanofi will assume and repay Inhibrx's outstanding third-party debt and will finance New Inhibrx with $200 million in cash (€183 million) and retain...
In 2021, Teva's Spanish subsidiary had a turnover of around 412 million euros in a global context of slowing turnover, which in 2022 fell by 6%....
The second Spanish biotech company most endorsed by investors last year was the Valencian Arthex Biotech, protagonist of a round of 42 million. Specialized in therapies...
The presentation of the results was scheduled for the end of February, but Grifols wants to move forward so that the situation is not unsustainable for...
The distribution model in Italy is made up of manufacturing industries and pharmacies which is essentially based on the classic customer-supplier relationship or on the establishment...
A week ago, BioNTech presented its billing forecasts for 2024, with the aim of reaching €3 billion. The figure represents a significant decrease in value compared...